Jason Steiner, Ph.D., Chief Strategy Officer at Synthego, leads the company's business strategy and partnership efforts to enable academic institutions and biotech and pharmaceutical companies to leverage Synthego’s gene engineering platform to accelerate the research, discovery and development of next-generation therapeutics, including genetic and cellular therapies. Before Synthego, Steiner spent several years in the clinical genomics space, commercializing liquid biopsy technologies in reproductive genetics and oncology at Natera.
He holds a doctoral degree in materials science engineering from the University of California, San Diego, where his research focused on the development of nanoparticle delivery systems for therapeutics and diagnostics in oncology. Steiner’s industry experience includes market development to support product launches across four continents and building and scaling commercial organizations across marketing, product development, sales and business development. Steiner also has served as the CEO of a non-profit entity focused on entrepreneurship. His dedication to biopharma is inspired by mission-driven travels, writing and business ventures.
CRISPR-based genome engineering enables researchers to study how SARS-CoV-2 interacts with human cells and generate the appropriate cell models that could lead to faster discovery of a potential new treatment or an existing drug combination that may provide a treatment solution.